# A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males

> **NCT01843556** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Elderly Male

## Interventions

- **DRUG:** E2022 Tape Formulation

## Key facts

- **NCT ID:** NCT01843556
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843556, "A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01843556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*